α-glucosidase inhibitors, including acarbose, voglibose and miglitol, are the first-line drugs in noninsulin-dependent T2DM characterized by their high efficacy in postponing the digestion of carbohydrates and reducing postprandial hyperglycemia (Montandon and Jornayvaz, 2017), those medications inhibit carbohydrate hydrolysis by binding to human intestinal maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI), and consequently delay and reduce the absorption of glucose. This evidence concerns the gene SI and Hyperglycemia.